Role of epigenomics in drug Discovery and therapies

Drug Development Research

Volumn 73, Issue 8, 2012, Pages 513-517

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

DNA methylation; epigenomics; histones; microRNA; pharmacogenomics

Indexed keywords

HISTONE; HORMONE; MICRORNA; TOXIN; TRANSFER RNA;

ACETYLATION; AGE; CELL FUNCTION; DISEASE PREDISPOSITION; DNA METHYLATION; DNA MODIFICATION; DRUG RESPONSE; EPIGENETICS; GENOME; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MENTAL DISEASE; MONOZYGOTIC TWINS; NONHUMAN; NUTRITION; PHARMACEUTICAL CARE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW;

EID: 84870881790     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21044     Document Type: Review

References (61)

1. Abdolmaleky HM, Zhou JR, Thiagalingam S, Smith CL,. 2008. Epigenetic and pharmacoepigenomic studies on major psychoses and potentials for therapeutics. Pharmacogenomics 9: 1809-1823.
2. Anttila S, Hakkola J, Touminen P, Elovaara E, Husgafvel-Pursiainen K, Karjalainen A, Hirvonen A, Nurminen T,. 2003. Methylation of cytochrome P 450 1A1 promoter in the lung is associated with tobacco smoking. Cancer Res 63: 8623-8628.
3. Baer-Dubowska W, Majchrzak-Celinska A, Cichocki M,. 2011. Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 63: 293-304.
4. Bell JT, Saffery R,. 2012. The value of twins in epigenetic epidemiology. Int J Epidemiol 41: 140-150.
5. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM,. 2010. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463: 1042-1047.
6. Bock C,. 2009. Epigenetic biomarker development. Epigenomics 1: 99-110.
7. Carlquist JF, Anderson JL,. 2011. Pharmacogenetic mechanisms underlying unanticipated drug responses. Discov Med 11: 469-478.
8. Chahwan R, Wontakal SN, Roa S,. 2011. The multidimensional nature of epigenetic information and its role in disease. Discov Med 11: 233-243.
9. Chen Z-X, Riggs AD,. 2011. DNA methylation and demethylation in mammals. J Biol Chem 286: 18347-18353.
10. Chik F, Szyf M, Rabbani SA,. 2011. Role of epigenetics in cancer initiation and progression. Adv Exp Med Biol 720: 91-104.
11. Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, Grunnet LG, Mandrup-Poulsen T,. 2011. Histone deacetylase inhibition as a novel treatment for diabetes mellitus. Mol Med 17: 378-390.
12. Claes B, Buysschaert I, Lambrechts D,. 2010. Pharmacoepigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity 105: 152-160.
13. Costa FF,. 2009. Non-coding RNAs and new opportunities for the private sector. Drug Discov Today 14: 446-452.
14. Dempster EL, Pidsley R, Schalkwyk LC, Owen S, Georgiades A, Kane F, Kalidindi S, Picchioni M, Kravariti E, Toulopoulou T, et al. 2011. Disease associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 20: 4786-4796.
15. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Torger M, Azaz-Livshits T, Levy M, Brune K, Hahan EG,. 2004. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Int Med 255: 653-663.
16. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS,. 2011. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 79: 23-32.
17. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, et al. 2005. Epigenetic differences arise during lifetime of monozygotic twins. Proc Natl Acad Sci. USA 102: 10604-10609.
18. Gal-Yam EN, Saito Y, Egger G, Jones PA,. 2008. Cancer epigenetics: modification, screening and therapy. Ann Rev Med 59: 267-280.
19. Gomez A, Ingleman-Sundberg M,. 2009a. Epigenetic and microRNA dependent control of cytochrome P 450 expression: a gap between DNA and protein. Pharmacogenomics 10: 1067-1076.
20. Gomez A, Ingleman-Sundberg M,. 2009b. Pharmacoepigenetics: its role in inter-individual differences in drug response. Clin Pharmacol Ther 85: 426-430.
21. Hamm CA, Costa FF,. 2011. The impact of epigenomics on future drug design and new therapies. Drug Discov Today 16: 626-635.
22. Hamm CA, Stevens JW, Xie H, Vanin EF, Morcuende JA, Abdulkawy H, Seftor EA, Sredni ST, Bischof JM, Wang D, et al. 2010. Micro-environment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors. BMC Cancer 10: 471. doi: 10.1186/1471-2407-10-471.
23. Hammons GJ, Yan-Sanders Y, Jin B, Blann E, Kadlubar FF, Lyn-Cook BD,. 2001. Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human liver. Life Sci 69: 839-845.
24. Hauser AT, Jung M,. 2008. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med 74: 1593-1601.
25. He F, Todd PK,. 2011. Epigenetics in nucleotide repeat expansion disorders. Semin Neurol 31: P470-P483.
26. Hou L, Zhang X, Wang D, Baccarelli A,. 2012. Environmental chemical exposures and human epigenetics. Int J Epidemiol 41: 79-105.
27. Ingleman-Sundberg M, Gomez A,. 2010. The past, present and future of pharmacoepigenomics. Pharmacogenomics 11: 625-627.
28. Ingleman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C,. 2007. Influence of cytochrome P 450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526.
29. Katada S, Imhof A, Sassone-Corsi P,. 2012. Connecting threads: epigenetics and metabolism. Cell 148: 24-28.
30. Kim DH, Rossi JJ,. 2008. RNAi mechanisms and applications. Biotechniques 44: 613-616.
31. Lamba V, Panetta JC, Storm S, Schuetz EG,. 2010. Genetic predictors of individual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 332: 1088-1099.
32. Lazarou J, Pomeranz BH, Corey PN,. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200-1205.
33. Leach TM, van der Harst P, de Boer RA,. 2010. Pharmacoepigenetics in heart failure. Curr Heart Fail Rep 7: 83-90.
34. Lemoine M, Younes A,. 2010. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 10: 462-470.
35. Merbs SL, Khan MA, Heckler L Jr, Oliver VF, Wan J, Qian J, Zack DJ,. 2012. Cell-specific DNA methylation patterns of retina-specific genes. PLoS ONE 7: e32602.
36. Nakajima M, Iwanari M, Yokoi T,. 2003. Effect of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expression of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett 144: 247-256.
37. Pan YZ, Gao W, Yu AM,. 2009. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37: 2112-2117.
38. Park JH, Park J, Choi JK, Lyu J, Bae MG, Lee YG, Bae JB, Park DY, Yang HK, Kim TY, et al. 2011. Identification of DNA methylation changes associated with human gastric cancer. BMC Med Genomics 4: 82.
39. Peedicayil J,. 2006. Epigenetic therapy-a new development in pharmacology. Indian J Med Res 123: 17-24.
40. Peedicayil J,. 2008. Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 9: 1785-1786.
41. Pinney SE, Simmons RA,. 2012. Metabolic programming, epigenetics and gestational diabetes mellitus. Curr Diab Rep 12: 67-74.
42. Ptak C, Petronis A,. 2008. Epigenetic and complex diseases: from etiology to new therapeutics. Ann Rev Pharmacol Toxicol 48: 257-276.
43. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Inglemann-Sundberg M,. 2010. Molecular genetics and epigenetics of cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 127: 1-17.
44. Rodriguez-Cerdeira C, Molanes-Vila A,. 2011. New perspectives of "omics" applications in melanoma research. Open Biochem J 5: 60-66.
45. Seddon JM, Reynolds R, Shah HR, Rosner B,. 2011. Smoking, dietary betaine, methionine and vitamin D, in monozygotic twins with discordant macular degeneration: epigenetic implications. Ophthalmology 118: 1386-1394.
46. Shastry BS,. 2006. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6: 16-21.
47. Shastry BS,. 2011. Pharmacogenomics in ophthalmology. Discov Med 12: 159-167.
48. Shomron N,. 2010. MicroRNAs and pharmacogenomics. Pharmacogenomics 11: 629-632.
49. Slomko H, Heo HJ, Einstein FH,. 2012. Minireview: epigenetics of obesity and diabetes in humans. Endocrinology 153: 1025-1030.
50. Smits KM, Cleven AH, Weijenberg MP, Hughes LA, Herman JG, de, Bruine AP, van, Engeland M,. 2008. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics 9: 1903-1916.
51. Szyf M,. 2004. Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2: 357-377.
52. Tahillani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
53. Toyota M, Suzuki H, Yamashita T, Hirata K, Imai K, Tokino T, Shinomura Y,. 2009. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 100: 787-791.
54. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T,. 2006. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66: 9090-9098.
55. Urdinguio RG, Sanchez-Mut JV, Esteller M,. 2009. Epigenetic mechanisms in neurological diseases: genes, syndromes and therapies. Lancet Neurol 8: 1056-1072.
56. Wagner KD, Wagner N, Ghanbarian H, Grandjean V, Gounon P, Cuzin F, Rassoulzadegan M,. 2008. RNA induction and inheritance of epigenetic cardiac hypertrophy in the mouse. Dev Cell 14: 962-969.
57. Wang SC, Oelze B, Schumacher A,. 2008. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE 3: e2698.
58. Zaidi SK, Young DW, Montecino M, van, Wijnen AJ, Stein JL, Lian JB, Stein GS,. 2011. Book marking the genome: maintenance of epigenetic information. J Biol Chem 286: 18355-18361.
59. Zhang B, Farwell MA,. 2008. MicroRNAs: a new emerging class of players for disease diagnostic and gene therapy. J Cell Mol Med 12: 3-21.
60. Zhang X, Rossi JJ,. 2011. Phylogenetic comparison of small RNA-triggered transcriptional gene silencing. J Biol Chem 286: 29443-29448.
61. Zimmer V, Lammert F,. 2011. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol 25: 269-280.